Results 141 to 150 of about 102,013 (267)

Cost-effectiveness of maternal and neonatal health interventions in Ethiopia: a systematic review and meta-analysis. [PDF]

Health Econ Rev
Sima AD, Burayu ET, Zegeye ZB.
europepmc   +1 more source

A sustainable business ecosystem: a case study demonstrating biochar's potential

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract The need for renewable, climate‐friendly resources has become urgent as legislators worldwide have sought to find ways to cut emissions while ensuring resource security for consumers. The use of biochar could help to achieve these goals. This study examines the current state of commercial biochar production and the maturity of the related ...
Juuso Kivijakola, Eemeli Erkheikki, Viljo Lukka, Pekka Tervonen, Harri Haapasalo   +4 more
wiley   +1 more source

Equity impact and cost-effectiveness of a community health worker breast cancer educational programme in rural South Africa: a modelling study. [PDF]

BMJ Open
Chanakira EZ, Thomas C, Miot J, Mandrik O.   +3 more
europepmc   +1 more source

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

British Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić, Elvira Meni Maria Gkrinia, Patrick Eustaquio, Andrea Katrin Faour, Dinko Vitezić   +4 more
wiley   +1 more source

Incorporating an equity perspective in systematic reviews of interventions: potential methodological approaches. [PDF]

J Epidemiol Community Health
Campbell M, Melendez-Torres GJ, Welch V, Petkovic J, Curtis F, Katikireddi SV.   +5 more
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Mapping the landscape of state Medicaid policy. [PDF]

Health Aff Sch
Beals G, Rivera M, Michener J.
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Open-Source Large Language Models and AI Health Equity: A Health Service Triangle Model Perspective. [PDF]

J Med Internet Res
Wu S, Zou W, Tu J, Wang C, Jin C, Liao J, Tang KC, Liu N, Hao C.   +8 more
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source